HC Wainwright Reaffirms “Buy” Rating for Delcath Systems (NASDAQ:DCTH)

Delcath Systems (NASDAQ:DCTHGet Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Friday, MarketBeat.com reports. They currently have a $29.00 target price on the stock, up from their previous target price of $24.00. HC Wainwright’s target price indicates a potential upside of 80.01% from the company’s previous close. HC Wainwright also issued estimates for Delcath Systems’ Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.14 EPS, Q3 2026 earnings at $0.25 EPS and Q4 2026 earnings at $0.34 EPS.

Delcath Systems Price Performance

Shares of DCTH stock opened at $16.11 on Friday. Delcath Systems has a fifty-two week low of $6.33 and a fifty-two week high of $18.23. The stock’s 50-day moving average is $13.05 and its two-hundred day moving average is $12.99. The firm has a market cap of $561.05 million, a P/E ratio of -11.93 and a beta of 0.72.

Delcath Systems (NASDAQ:DCTHGet Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.07). The firm had revenue of $19.80 million during the quarter, compared to analyst estimates of $16.83 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. As a group, research analysts expect that Delcath Systems will post -0.79 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds have recently bought and sold shares of the business. Vivo Capital LLC increased its holdings in shares of Delcath Systems by 71.4% during the 4th quarter. Vivo Capital LLC now owns 1,708,579 shares of the company’s stock valued at $20,571,000 after acquiring an additional 711,574 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Delcath Systems by 13.8% in the first quarter. Vanguard Group Inc. now owns 1,394,028 shares of the company’s stock worth $17,746,000 after buying an additional 169,260 shares during the last quarter. Soleus Capital Management L.P. bought a new stake in shares of Delcath Systems during the 4th quarter worth $9,644,000. Gilder Gagnon Howe & Co. LLC acquired a new position in Delcath Systems during the 4th quarter worth $7,371,000. Finally, Millennium Management LLC increased its stake in shares of Delcath Systems by 34.1% in the first quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock worth $5,373,000 after purchasing an additional 107,391 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Read More

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.